Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

34.18
-1.1000-3.12%
Volume:1.59M
Turnover:54.85M
Market Cap:5.93B
PE:-15.82
High:35.57
Open:35.09
Low:34.08
Close:35.28
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:1.14
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:12.68
PE(LYR):-13.40

Loading ...

Biohaven Q2 Net Loss Narrows on Lower R&D Spend

Reuters
·
Aug 11

Septerna Q2 Revenue Beats Analyst Estimates, Driven by Novo Nordisk Partnership

Reuters
·
Aug 11

Cogent Biosciences Q2 Loss Widens

MT Newswires Live
·
Aug 10

Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, vs. FactSet Est of $98M Loss

MT Newswires Live
·
Aug 10

Cogent Biosciences Q2 Net Income USD -96.405 Million

Reuters
·
Aug 10

Cogent Biosciences Q2 Operating Expenses USD 102.638 Million

THOMSON REUTERS
·
Aug 10

Cogent Biosciences - Submits Nda to FDA for Bezuclastinib in Advanced Systemic Mastocytosis

THOMSON REUTERS
·
Jun 30

Cogent Biosciences Submits FDA NDA for Bezuclastinib in Advanced Systemic Mastocytosis

Reuters
·
Jun 30

Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base

Simply Wall St.
·
Jun 30

H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Jun 17

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Wedbush Keeps Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Jun 15

Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed

Simply Wall St.
·
Jun 13

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

MT Newswires Live
·
Jun 12

Cogent Biosciences - Bezuclastinib Continues to Show Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jun 12

Cogent Biosciences - to Submit Apex Nda in June 2026

THOMSON REUTERS
·
Jun 12

Cogent Biosciences - Bezuclastinib Shows 65% Orr per Miwg and 81% Orr per Ppr in Advsm Patients

THOMSON REUTERS
·
Jun 12

Cogent Biosciences says mutant-selective JAK2 V617F inhibitor CGT1145 on track for IND in 2026

Reuters
·
Jun 12

Cogent says bezuclastinib posts 65% response rate in APEX trial for advanced systemic mastocytosis

Reuters
·
Jun 12

Cogent Biosciences shareholders elect directors at annual meeting

Reuters
·
Jun 12